摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonthioamide | 57944-10-2

中文名称
——
中文别名
——
英文名称
2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonthioamide
英文别名
3,4,6-tri-O-benzoyl-β-D-allonthioamide;tri-O-benzoyl-D-2,5-anhydro-allonothioic acid amide;(2R,3R,4R,5R)-2-((Benzoyloxy)methyl)-5-carbamothioyltetrahydrofuran-3,4-diyl dibenzoate;[(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-carbamothioyloxolan-2-yl]methyl benzoate
2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonthioamide化学式
CAS
57944-10-2
化学式
C27H23NO7S
mdl
——
分子量
505.548
InChiKey
CKTMVNDDGTXBJC-SSGKUCQKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    乙醇、乙酸乙酯

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    36
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    146
  • 氢给体数:
    1
  • 氢受体数:
    8

SDS

SDS:804f8eb54e7c4980fcda65d9abd7637b
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Procedures for obtaining ribo-C-nucleosides
    申请人:ICN Pharmaceuticals, Inc.
    公开号:US05907036A1
    公开(公告)日:1999-05-25
    Novel procedures for obtaining ribo-C-nucleosides, including especially 2-.beta.-D-ribofuranosylthiazole-4-carboxylamide (tiazofirin) and 2-.beta.-D-ribofuranosylselenazole-4-carboxylamide (sylenazofurin) and synthesis intermediates thereof. The novel procedures involve introducing a cyano group at the 1' position of a ribose, directly or indirectly converting the cyano group to HN.dbd.C--OR.sub.1 or thicarboxylamide wherein R.sub.1 is a lower alkyl, forming the group which substituted for the cyano group into a heterocyclic ring containing an ester, and converting the ester into an amide.
    获得核糖C核苷的新方法,特别是2-β-D-核糖呋喃基噻唑-4-羧酰胺(噻唑呋喃)和2-β-D-核糖呋喃基硒唑-4-羧酰胺(硒唑呋喃)及其合成中间体。这些新方法涉及在核糖的1'位置引入氰基,直接或间接地将氰基转化为HN.dbd.C--OR.sub.1或硫代羧酰胺,其中R.sub.1是较低的烷基,将替代氰基的基团形成一个含有酯的杂环环,并将酯转化为酰胺。
  • Process for the production of
    申请人:The United States of America as represented by the Department of Health
    公开号:US04451648A1
    公开(公告)日:1984-05-29
    An improved multi-step process for the production of 2-.beta.-D-ribofuranosylthiazole-4-carboxamide.
    生产2-β-D-核糖呋喃噻唑-4-甲酰胺的改进多步工艺。
  • Synthesis and antiviral activity of certain thiazole C-nucleosides
    作者:Prem C. Srivastava、Michael V. Pickering、Lois B. Allen、David G. Streeter、Marie T. Campbell、Joseph T. Witkowski、Robert W. Sidwell、Roland K. Robins
    DOI:10.1021/jm00212a014
    日期:1977.2
    glycosylthiocarboxamides were utilized as the precursors for the synthesis of 2-D-ribofuranosylthiazole-4-carboxamide and 2-beta-D-ribofuranosylthiazole-5-carboxamide (23). The structural modification of 2-beta-D-ribofuranosylthiazole-4-carboxamide (12) into 2-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)thiazole-4-carboxamide (15), 2-beta-D-ribofuranosylthiazole-4-thiocarboxamide (17), and 2-(5-deoxy-beta-D-ribofuranos
    描述了在4-二甲基氨基吡啶存在下,糖基氰化物与液态硫化氢的一般反应,以提供相应的糖基硫代羧酰胺。这些糖基硫代羧酰胺被用作合成2-D-呋喃呋喃糖基噻唑-4-羧酰胺和2-β-D-呋喃呋喃糖基噻唑-5-羧酰胺的前体(23)。2-β-D-呋喃呋喃糖基噻唑-4-羧酰胺(12)的结构修饰为2-(2,3,5-三-O-乙酰基-β-D-呋喃呋喃糖基)噻唑-4-甲酰胺(15),2还描述了-β-D-呋喃呋喃糖基噻唑-4-硫代羧酰胺(17)和2-(5-脱氧-β-D-呋喃呋喃糖基)噻唑-4-甲酰胺(19)。测试了这些噻唑核苷对1型疱疹病毒,3型副流感病毒和13型鼻病毒的体外活性,并进行了针对副流感病毒的体内实验。他们还被评估为嘌呤核苷酸生物合成的潜在抑制剂。已显示具有最显着的抗病毒活性的化合物(12和15)也是鸟嘌呤核苷酸生物合成的活性抑制剂(40-70%)。
  • Non-natural carbon-linked nucleotides and dinucleotides
    申请人:Mack Robert Stephen
    公开号:US20050009777A1
    公开(公告)日:2005-01-13
    Nucleotide derivatives of formula (1) are described, wherein: G is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, aromatic or heteroaromatic group or a non natural carbon-linked nucleoside as defined herein; G′ is a non-natural carbon-linked nucleoside as defined herein; n is zero, or the integer 1 or 2; m is zero or the integer 1 or 2; and the salts, solvates, hydrates and N-oxides thereof. The compounds are P2Y receptor agonists and are of use in the prophylaxis and treatment of diseases and disorders involving abnormal secretory mechanisms such as inadequate functioning of mucociliary clearance mechanisms or abnormal tear secretion or in the treatment of diseases involving inappropriate cellular glucose uptake.
    本文描述了式(1)的核苷酸衍生物,其中:G是氢原子或可选取代的脂肪族,杂脂族,环脂族,多环脂族,芳香族或杂芳香族基团或非天然的碳链核苷酸,如本文所定义;G'是本文所定义的非天然碳链核苷酸;n为零或整数1或2;m为零或整数1或2;以及其盐,溶剂合物,水合物和N-氧化物。这些化合物是P2Y受体激动剂,可用于预防和治疗涉及异常分泌机制的疾病和障碍,例如粘液纤毛清除机制的功能不足或泪液分泌异常,或用于治疗涉及不适当细胞葡萄糖摄取的疾病。
  • Process for the production of 2-beta-D-ribofuranosylthiazole-4-carboxamide
    申请人:Starks Associates, Incorporated
    公开号:EP0072977A1
    公开(公告)日:1983-03-02
    An improved multi-step process for the production of 2-β-D-ribofuranosylthiazole-4-carboxamide: 2,3,5-Tri-O-benzoyl-D-ribofuranosyl bromide 2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl cyanide 2,5-Anhydro-3,4,6-tri-O-benzoyl-D-allonthioamide Thiazole-4-carboxylic acid 2-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-, ethyl ester 2-β-D-ribofuranosylthiazole-4-carboxylic acid, methyl ester 2-β-D-ribofuranosylthiazole-4-carboxamide
    生产 2-β-D-ribofuranosylthiazole-4-carboxamide 的改进型多步骤工艺: 2,3,5-三-O-苯甲酰基-D-呋喃核糖溴化物 2,3,5-三-O-苯甲酰基-β-D-呋喃核糖氰化物 2,5-脱水-3,4,6-三-O-苯甲酰基-D-异戊酰胺 噻唑-4-羧酸 2-(2',3',5'-三-O-苯甲酰基-β-D-呋喃核糖基)-乙酯 2-β-D-呋喃核糖基噻唑-4-甲酸甲酯 2-β-D-呋喃核糖基噻唑-4-甲酰胺
查看更多